Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other

Better Therapeutics First Patient Enrolled in BT-001 Trial for T2DM; ProtoKinetix Resumes Islet Ph1 Trials in T1DM; Amarin Receives Great Britain Marketing Authorization Approval for Vazkepa CV Risk Reduction

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Better Therapeutics announced the first patient has been enrolled in a pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of T2DM; ProtoKinetix announced it has resumed the Ph1 trials of PKX-001 treated islet cells following a pause due to COVID-19; and Amarin announced it received Great Britain Marketing Authorization approval of Vazkepa (icosapent ethyl) to reduce the risk of CV events in high-risk, statin-treated adults with elevated triglycerides (≥150 mg/dL) and either established CVD or diabetes and at least one additional CV risk factor. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.